Skip to main content
Erschienen in: Inflammation 3/2013

01.06.2013

Is the CCR5 Δ 32 Mutation Associated with Immune System-Related Diseases?

verfasst von: Khodayar Ghorban, Maryam Dadmanesh, Gholamhossein Hassanshahi, Mohammad Momeni, Mohammad Zare-Bidaki, Mohammad Kazemi Arababadi, Derek Kennedy

Erschienen in: Inflammation | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Hypersensitivity and autoimmunity are the main features of immune system-related diseases such as type 2 diabetes (T2D), multiple sclerosis (MS), and asthma. It has been established that chemokines play key roles in the activation and regulation of immune cell migration which is important in the pathogenesis of the diseases mentioned. CC chemokines receptor 5 or CCR5 is a receptor for RANTES, MIP-1α, and MIP-1β and is expressed by several immune cells including NK cells, T lymphocytes, and macrophages. It plays key roles in the regulation of migration and activation of the immune cells during immune responses against microbe and self-antigens during autoimmunity and hypersensitivity disorders. Therefore, any alteration in the sequence of CCR5 gene or in its expression could be associated with immune system-related diseases. Previous studies revealed that a 32-base pair deletion (Δ 32) in exon 1 of the CCR5 gene led to downregulation of the gene. Previous studies demonstrated that not only CCR5 expression was altered in autoimmune and hypersensitivity disorders, but also that the mutation is associated with the diseases. This review addresses the recent information regarding the association of the CCR5 Δ 32 mutation in immune-related diseases including T2D with and without nephropathy, MS, and asthma. Based on the collected data, it seems that the CCR5 Δ 32 mutation can be considered as a risk factor for MS, but not asthma and T2D with and without nephropathy.
Literatur
1.
Zurück zum Zitat Chiang, Y.J., H.K. Kole, K. Brown, et al. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403: 216–220.PubMedCrossRef Chiang, Y.J., H.K. Kole, K. Brown, et al. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403: 216–220.PubMedCrossRef
2.
Zurück zum Zitat Arababadi M. K., Ahmadabadi B. N., Kennedy D. 2012. Current information on the immunological status of occult hepatitis B infection. Transfusion 52: 1819–1826. Arababadi M. K., Ahmadabadi B. N., Kennedy D. 2012. Current information on the immunological status of occult hepatitis B infection. Transfusion 52: 1819–1826.
3.
Zurück zum Zitat van Eden, W., A. Koets, P. van Kooten, et al. 2003. Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 21: 897–901.PubMedCrossRef van Eden, W., A. Koets, P. van Kooten, et al. 2003. Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 21: 897–901.PubMedCrossRef
4.
Zurück zum Zitat Miyara, M., K. Wing, and S. Sakaguchi. 2009. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J Allergy Clin Immunol 123: 749–755. quiz 756–747.PubMedCrossRef Miyara, M., K. Wing, and S. Sakaguchi. 2009. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J Allergy Clin Immunol 123: 749–755. quiz 756–747.PubMedCrossRef
5.
Zurück zum Zitat Al-Abdulhadi, S.A., and M.W. Al-Rabia. 2010. Linkage and haplotype analysis for chemokine receptors clustered on chromosome 3p21.3 and transmitted in family pedigrees with asthma and atopy. Ann Saudi Med 30: 115–122.PubMedCrossRef Al-Abdulhadi, S.A., and M.W. Al-Rabia. 2010. Linkage and haplotype analysis for chemokine receptors clustered on chromosome 3p21.3 and transmitted in family pedigrees with asthma and atopy. Ann Saudi Med 30: 115–122.PubMedCrossRef
6.
Zurück zum Zitat Lehner, T. 2002. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol 23: 347–351.PubMedCrossRef Lehner, T. 2002. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol 23: 347–351.PubMedCrossRef
7.
Zurück zum Zitat Ahmadabadi, B.N., G. Hassanshahi, H. Khoramdelazad, et al. 2012. Down-regulation of CCR5 expression on the peripheral blood CD8+ T cells of South-Eastern Iranian patients with chronic hepatitis B infection. Inflammation. doi:10.1007/s10753-012-9528-4. Ahmadabadi, B.N., G. Hassanshahi, H. Khoramdelazad, et al. 2012. Down-regulation of CCR5 expression on the peripheral blood CD8+ T cells of South-Eastern Iranian patients with chronic hepatitis B infection. Inflammation. doi:10.​1007/​s10753-012-9528-4.
8.
Zurück zum Zitat Song, J.K., M.H. Park, D.Y. Choi, et al. 2012. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and upregulation of IL-1Ra in melanoma model. PLoS One 7: e33747.PubMedCrossRef Song, J.K., M.H. Park, D.Y. Choi, et al. 2012. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and upregulation of IL-1Ra in melanoma model. PLoS One 7: e33747.PubMedCrossRef
9.
Zurück zum Zitat Kuipers, H.F., P.J. Biesta, L.J. Montagne, et al. 2008. CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. Blood 112: 1610–1619.PubMedCrossRef Kuipers, H.F., P.J. Biesta, L.J. Montagne, et al. 2008. CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. Blood 112: 1610–1619.PubMedCrossRef
10.
Zurück zum Zitat Blanpain, C., F. Libert, G. Vassart, et al. 2002. CCR5 and HIV infection. Receptors Channels 8: 19–31.PubMedCrossRef Blanpain, C., F. Libert, G. Vassart, et al. 2002. CCR5 and HIV infection. Receptors Channels 8: 19–31.PubMedCrossRef
11.
Zurück zum Zitat Sorce, S., R. Myburgh, and K.H. Krause. 2011. The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 93: 297–311.PubMedCrossRef Sorce, S., R. Myburgh, and K.H. Krause. 2011. The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 93: 297–311.PubMedCrossRef
12.
Zurück zum Zitat Wong, M., S. Uddin, B. Majchrzak, et al. 2001. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 276: 11427–11431.PubMedCrossRef Wong, M., S. Uddin, B. Majchrzak, et al. 2001. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 276: 11427–11431.PubMedCrossRef
13.
Zurück zum Zitat Arababadi, M.K., A.A. Pourfathollah, A. Jafarzadeh, et al. 2010. Decreased expression of CCR5 on the NK cells in occult HBV infected patients. LabMedicine 41: 735–738. Arababadi, M.K., A.A. Pourfathollah, A. Jafarzadeh, et al. 2010. Decreased expression of CCR5 on the NK cells in occult HBV infected patients. LabMedicine 41: 735–738.
14.
Zurück zum Zitat Jin, Q., L. Agrawal, L. Meyer, et al. 2008. CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects. J Virol 82: 2418–2426.PubMedCrossRef Jin, Q., L. Agrawal, L. Meyer, et al. 2008. CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects. J Virol 82: 2418–2426.PubMedCrossRef
15.
Zurück zum Zitat Singh, H., R. Sachan, M. Jain, et al. 2008. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res 17: 87–91.PubMed Singh, H., R. Sachan, M. Jain, et al. 2008. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res 17: 87–91.PubMed
16.
Zurück zum Zitat Nahon, P., A. Sutton, P. Rufat, et al. 2008. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 14: 713–719.PubMedCrossRef Nahon, P., A. Sutton, P. Rufat, et al. 2008. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 14: 713–719.PubMedCrossRef
17.
Zurück zum Zitat Guerini, F.R., S. Delbue, M. Zanzottera, et al. 2008. Analysis of CCR5, CCR2, SDF1 and RANTES gene polymorphisms in subjects with HIV-related PML and not determined leukoencephalopathy. Biomed Pharmacother 62: 26–30.PubMedCrossRef Guerini, F.R., S. Delbue, M. Zanzottera, et al. 2008. Analysis of CCR5, CCR2, SDF1 and RANTES gene polymorphisms in subjects with HIV-related PML and not determined leukoencephalopathy. Biomed Pharmacother 62: 26–30.PubMedCrossRef
18.
Zurück zum Zitat Abousaidi, H., R. Vazirinejad, M.K. Arababadi, et al. 2011. Lack of association between chemokine receptor 5 (CCR5) delta32 mutation and pathogenesis of asthma in Iranian patients. South Med J 104: 422–425.PubMedCrossRef Abousaidi, H., R. Vazirinejad, M.K. Arababadi, et al. 2011. Lack of association between chemokine receptor 5 (CCR5) delta32 mutation and pathogenesis of asthma in Iranian patients. South Med J 104: 422–425.PubMedCrossRef
19.
Zurück zum Zitat Richardson, M.W., J. Jadlowsky, C.A. Didigu, et al. 2012. Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. J Immunol 189: 3815–3821.PubMedCrossRef Richardson, M.W., J. Jadlowsky, C.A. Didigu, et al. 2012. Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. J Immunol 189: 3815–3821.PubMedCrossRef
20.
Zurück zum Zitat Liu, S., C. Kong, J. Wu, et al. 2012. Effect of CCR5-Delta32 heterozygosity on HIV-1 susceptibility: a meta-analysis. PLoS One 7: e35020.PubMedCrossRef Liu, S., C. Kong, J. Wu, et al. 2012. Effect of CCR5-Delta32 heterozygosity on HIV-1 susceptibility: a meta-analysis. PLoS One 7: e35020.PubMedCrossRef
21.
Zurück zum Zitat Muntinghe, F.L., S. Gross, S.J. Bakker, et al. 2009. CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus. Diabetes Res Clin Pract 86: 140–145.PubMedCrossRef Muntinghe, F.L., S. Gross, S.J. Bakker, et al. 2009. CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus. Diabetes Res Clin Pract 86: 140–145.PubMedCrossRef
22.
Zurück zum Zitat Sellebjerg, F., H.O. Madsen, C.V. Jensen, et al. 2000. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 102: 98–106.PubMedCrossRef Sellebjerg, F., H.O. Madsen, C.V. Jensen, et al. 2000. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 102: 98–106.PubMedCrossRef
23.
Zurück zum Zitat Bisset, L.R., and P. Schmid-Grendelmeier. 2005. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med 11: 35–42.PubMedCrossRef Bisset, L.R., and P. Schmid-Grendelmeier. 2005. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med 11: 35–42.PubMedCrossRef
24.
Zurück zum Zitat Cookson, W. 1999. The alliance of genes and environment in asthma and allergy. Nature 402: B5–11.PubMedCrossRef Cookson, W. 1999. The alliance of genes and environment in asthma and allergy. Nature 402: B5–11.PubMedCrossRef
25.
Zurück zum Zitat Orihara, K., N. Dil, V. Anaparti, et al. 2011. What's new in asthma pathophysiology and immunopathology? Expert Rev Respir Med 4: 605–629.CrossRef Orihara, K., N. Dil, V. Anaparti, et al. 2011. What's new in asthma pathophysiology and immunopathology? Expert Rev Respir Med 4: 605–629.CrossRef
26.
Zurück zum Zitat Sawcer, S., G. Hellenthal, M. Pirinen, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–219.PubMedCrossRef Sawcer, S., G. Hellenthal, M. Pirinen, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–219.PubMedCrossRef
27.
Zurück zum Zitat Arababadi, M.K., R. Mosavi, H. Khorramdelazad, et al. 2010. Cytokine patterns after therapy with Avonex(R), Rebif(R), Betaferon(R) and CinnoVex in relapsing-remitting multiple sclerosis in Iranian patients. Biomark Med 4: 755–759.PubMedCrossRef Arababadi, M.K., R. Mosavi, H. Khorramdelazad, et al. 2010. Cytokine patterns after therapy with Avonex(R), Rebif(R), Betaferon(R) and CinnoVex in relapsing-remitting multiple sclerosis in Iranian patients. Biomark Med 4: 755–759.PubMedCrossRef
28.
Zurück zum Zitat Arababadi M. K., Mosavi R., Teimori H., et al. 2011. Association of IL-4 polymorphisms with multiple sclerosis in south-eastern Iranian patients. Ann Saudi Med 32: 127–130. Arababadi M. K., Mosavi R., Teimori H., et al. 2011. Association of IL-4 polymorphisms with multiple sclerosis in south-eastern Iranian patients. Ann Saudi Med 32: 127–130.
29.
Zurück zum Zitat Yaghini N., Mahmoodi M., Asadikaram G., et al. 2012. Genetic variation of IL-12B (+1188 region) is associated with its decreased circulating levels and susceptibility to type 2 diabetes: a study on south-eastern Iranian diabetic patients. Biomark Med 6: 89–95. Yaghini N., Mahmoodi M., Asadikaram G., et al. 2012. Genetic variation of IL-12B (+1188 region) is associated with its decreased circulating levels and susceptibility to type 2 diabetes: a study on south-eastern Iranian diabetic patients. Biomark Med 6: 89–95.
30.
Zurück zum Zitat Cruz, M., C. Maldonado-Bernal, R. Mondragon-Gonzalez, et al. 2008. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. J Endocrinol Invest 31: 694–699.PubMed Cruz, M., C. Maldonado-Bernal, R. Mondragon-Gonzalez, et al. 2008. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. J Endocrinol Invest 31: 694–699.PubMed
31.
Zurück zum Zitat Yaghini N., Mahmoodi M., Asadikaram G., et al. 2011. Serum levels of Interleukin 10 (IL-10) in patients with type 2 diabetes. Iran Red Cres Med J 13: 752. Yaghini N., Mahmoodi M., Asadikaram G., et al. 2011. Serum levels of Interleukin 10 (IL-10) in patients with type 2 diabetes. Iran Red Cres Med J 13: 752.
32.
Zurück zum Zitat Arababadi, M.K., R. Nosratabadi, G. Hassanshahi, et al. 2009. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? Diabetes Res Clin Pract 87: 33–37.PubMedCrossRef Arababadi, M.K., R. Nosratabadi, G. Hassanshahi, et al. 2009. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? Diabetes Res Clin Pract 87: 33–37.PubMedCrossRef
33.
Zurück zum Zitat Arababadi, M.K. 2010. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iran J Kidney Dis 4: 302–306. Arababadi, M.K. 2010. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iran J Kidney Dis 4: 302–306.
34.
Zurück zum Zitat Arababadi, M.K., A.A. Pourfathollah, S. Daneshmandi, et al. 2009. Evaluation of relation between IL-4 and IFN-g polymorphisms and type 2 diabetes. Iran J Bas Med Sci 12: 100–104. Arababadi, M.K., A.A. Pourfathollah, S. Daneshmandi, et al. 2009. Evaluation of relation between IL-4 and IFN-g polymorphisms and type 2 diabetes. Iran J Bas Med Sci 12: 100–104.
35.
Zurück zum Zitat Nosratabadi, R., M.K. Arababadi, V.A. Salehabad, et al. 2010. Polymorphisms within exon 9 but not intron 8 of the vitamin D receptor are associated with the nephropathic complication of type-2 diabetes. Int J Immunogenet 37: 1–5.CrossRef Nosratabadi, R., M.K. Arababadi, V.A. Salehabad, et al. 2010. Polymorphisms within exon 9 but not intron 8 of the vitamin D receptor are associated with the nephropathic complication of type-2 diabetes. Int J Immunogenet 37: 1–5.CrossRef
36.
Zurück zum Zitat Arababadi, M.K., N. Naghavi, G. Hassanshahi, et al. 2009. Is CCR5-Delta32 mutation associated with diabetic nephropathy in type 2 diabetes? Ann Saudi Med 29: 413.PubMedCrossRef Arababadi, M.K., N. Naghavi, G. Hassanshahi, et al. 2009. Is CCR5-Delta32 mutation associated with diabetic nephropathy in type 2 diabetes? Ann Saudi Med 29: 413.PubMedCrossRef
37.
Zurück zum Zitat Neumeier, M., S. Bauer, H. Bruhl, et al. 2011. Adiponectin stimulates release of CCL2, -3, -4 and -5 while the surface abundance of CCR2 and -5 is simultaneously reduced in primary human monocytes. Cytokine 56: 573–580.PubMedCrossRef Neumeier, M., S. Bauer, H. Bruhl, et al. 2011. Adiponectin stimulates release of CCL2, -3, -4 and -5 while the surface abundance of CCR2 and -5 is simultaneously reduced in primary human monocytes. Cytokine 56: 573–580.PubMedCrossRef
38.
Zurück zum Zitat Venza, I., M. Visalli, M. Cucinotta, et al. 2010. Proinflammatory gene expression at chronic periodontitis and peri-implantitis sites in patients with or without type 2 diabetes. J Periodontol 81: 99–108.PubMedCrossRef Venza, I., M. Visalli, M. Cucinotta, et al. 2010. Proinflammatory gene expression at chronic periodontitis and peri-implantitis sites in patients with or without type 2 diabetes. J Periodontol 81: 99–108.PubMedCrossRef
39.
Zurück zum Zitat Bogdanski, P., D. Pupek-Musialik, J. Dytfeld, et al. 2007. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. Int J Clin Pharmacol Ther 45: 563–567.PubMed Bogdanski, P., D. Pupek-Musialik, J. Dytfeld, et al. 2007. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. Int J Clin Pharmacol Ther 45: 563–567.PubMed
40.
Zurück zum Zitat Kalev, I., K. Oselin, P. Parlist, et al. 2003. CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. J Diabetes Complications 17: 387–391.PubMedCrossRef Kalev, I., K. Oselin, P. Parlist, et al. 2003. CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. J Diabetes Complications 17: 387–391.PubMedCrossRef
41.
Zurück zum Zitat Ahluwalia, T.S., M. Khullar, M. Ahuja, et al. 2009. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4: e5168.PubMedCrossRef Ahluwalia, T.S., M. Khullar, M. Ahuja, et al. 2009. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4: e5168.PubMedCrossRef
42.
Zurück zum Zitat Ascherio, A., K.L. Munger, and K.C. Simon. 2010. Vitamin D and multiple sclerosis. Lancet Neurol 9: 599–612.PubMedCrossRef Ascherio, A., K.L. Munger, and K.C. Simon. 2010. Vitamin D and multiple sclerosis. Lancet Neurol 9: 599–612.PubMedCrossRef
43.
Zurück zum Zitat Teunissen, C.E., J. Killestein, and G. Giovannoni. 2007. Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomark Med 1: 111–119.PubMedCrossRef Teunissen, C.E., J. Killestein, and G. Giovannoni. 2007. Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomark Med 1: 111–119.PubMedCrossRef
44.
Zurück zum Zitat Glass, C.K., K. Saijo, B. Winner, et al. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918–934.PubMedCrossRef Glass, C.K., K. Saijo, B. Winner, et al. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918–934.PubMedCrossRef
45.
Zurück zum Zitat Gandhi, R., A. Laroni, and H.L. Weiner. 2010. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 221: 7–14.PubMedCrossRef Gandhi, R., A. Laroni, and H.L. Weiner. 2010. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 221: 7–14.PubMedCrossRef
46.
Zurück zum Zitat Szczucinski, A., and J. Losy. 2007. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 115: 137–146.PubMedCrossRef Szczucinski, A., and J. Losy. 2007. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 115: 137–146.PubMedCrossRef
47.
Zurück zum Zitat Arababadi, M.K., G. Hassanshahi, H. Azin, et al. 2010. No association between CCR5-Δ 32 mutation and multiple sclerosis in patients of south-eastern of Iran. LabMedicine 41: 31–33. Arababadi, M.K., G. Hassanshahi, H. Azin, et al. 2010. No association between CCR5-Δ 32 mutation and multiple sclerosis in patients of south-eastern of Iran. LabMedicine 41: 31–33.
48.
Zurück zum Zitat Bennetts, B.H., S.M. Teutsch, M.M. Buhler, et al. 1997. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 58: 52–59.PubMedCrossRef Bennetts, B.H., S.M. Teutsch, M.M. Buhler, et al. 1997. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 58: 52–59.PubMedCrossRef
49.
Zurück zum Zitat Kantarci, O.H., Y. Morales, P.A. Ziemer, et al. 2005. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol 169: 137–143.PubMedCrossRef Kantarci, O.H., Y. Morales, P.A. Ziemer, et al. 2005. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol 169: 137–143.PubMedCrossRef
50.
Zurück zum Zitat Silversides, J.A., S.V. Heggarty, G.V. McDonnell, et al. 2004. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 10: 149–152.PubMedCrossRef Silversides, J.A., S.V. Heggarty, G.V. McDonnell, et al. 2004. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 10: 149–152.PubMedCrossRef
51.
Zurück zum Zitat Haase, C.G., S. Schmidt, and P.M. Faustmann. 2002. Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci Lett 330: 293–295.PubMedCrossRef Haase, C.G., S. Schmidt, and P.M. Faustmann. 2002. Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci Lett 330: 293–295.PubMedCrossRef
52.
Zurück zum Zitat Sellebjerg, F., T.B. Kristiansen, P. Wittenhagen, et al. 2007. Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand 115: 413–418.PubMedCrossRef Sellebjerg, F., T.B. Kristiansen, P. Wittenhagen, et al. 2007. Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand 115: 413–418.PubMedCrossRef
53.
Zurück zum Zitat Sellebjerg, F., G. Giovannoni, A. Hand, et al. 2002. Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis. J Neuroimmunol 125: 198–203.PubMedCrossRef Sellebjerg, F., G. Giovannoni, A. Hand, et al. 2002. Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis. J Neuroimmunol 125: 198–203.PubMedCrossRef
54.
Zurück zum Zitat Shahbazi, M., H. Ebadi, D. Fathi, et al. 2009. CCR5-delta32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol 29: 29.CrossRef Shahbazi, M., H. Ebadi, D. Fathi, et al. 2009. CCR5-delta32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol 29: 29.CrossRef
55.
Zurück zum Zitat Gade-Andavolu, R., D.E. Comings, J. MacMurray, et al. 2004. Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet Med 6: 126–131.PubMedCrossRef Gade-Andavolu, R., D.E. Comings, J. MacMurray, et al. 2004. Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet Med 6: 126–131.PubMedCrossRef
56.
Zurück zum Zitat Favorova, O.O., T.V. Andreewski, A.N. Boiko, et al. 2002. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology 59: 1652–1655.PubMedCrossRef Favorova, O.O., T.V. Andreewski, A.N. Boiko, et al. 2002. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology 59: 1652–1655.PubMedCrossRef
57.
Zurück zum Zitat D'Angelo, R., C. Crisafulli, C. Rinaldi, et al. 2011. CCR5Delta32 polymorphism associated with a slower rate disease progression in a cohort of RR-MS Sicilian patients. Mult Scler Int 2011: 153282.PubMed D'Angelo, R., C. Crisafulli, C. Rinaldi, et al. 2011. CCR5Delta32 polymorphism associated with a slower rate disease progression in a cohort of RR-MS Sicilian patients. Mult Scler Int 2011: 153282.PubMed
58.
Zurück zum Zitat Pulkkinen, K., M. Luomala, H. Kuusisto, et al. 2004. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand 109: 342–347.PubMedCrossRef Pulkkinen, K., M. Luomala, H. Kuusisto, et al. 2004. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand 109: 342–347.PubMedCrossRef
59.
Zurück zum Zitat Sandford, A.J., S. Zhu, T.R. Bai, et al. 2001. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol 108: 69–73.PubMedCrossRef Sandford, A.J., S. Zhu, T.R. Bai, et al. 2001. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol 108: 69–73.PubMedCrossRef
60.
Zurück zum Zitat Zietkowski, Z., M.M. Tomasiak, R. Skiepko, et al. 2008. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respir Med 102: 1198–1202.PubMedCrossRef Zietkowski, Z., M.M. Tomasiak, R. Skiepko, et al. 2008. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respir Med 102: 1198–1202.PubMedCrossRef
61.
Zurück zum Zitat Moore, K.W., R. de Waal Malefyt, R.L. Coffman, et al. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683–765.PubMedCrossRef Moore, K.W., R. de Waal Malefyt, R.L. Coffman, et al. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683–765.PubMedCrossRef
62.
Zurück zum Zitat Abousaidi H., Vazirinejad R., Arababadi M. K., et al. 2011. Lack of association between chemokine receptor 5 (CCR5) C32 mutation and pathogenesis of Asthma: A Study on Iranian Asthma Patients. South Med J 104: 422–425. Abousaidi H., Vazirinejad R., Arababadi M. K., et al. 2011. Lack of association between chemokine receptor 5 (CCR5) C32 mutation and pathogenesis of Asthma: A Study on Iranian Asthma Patients. South Med J 104: 422–425.
63.
Zurück zum Zitat Mitchell, T.J., A.J. Walley, J.E. Pease, et al. 2000. Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet 356: 1491–1492.PubMedCrossRef Mitchell, T.J., A.J. Walley, J.E. Pease, et al. 2000. Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet 356: 1491–1492.PubMedCrossRef
64.
Zurück zum Zitat Szalai, C., A. Bojszko, G. Beko, et al. 2000. Prevalence of CCR5delta32 in allergic diseases. Lancet 355: 66.PubMedCrossRef Szalai, C., A. Bojszko, G. Beko, et al. 2000. Prevalence of CCR5delta32 in allergic diseases. Lancet 355: 66.PubMedCrossRef
65.
Zurück zum Zitat Nagy, A., G.T. Kozma, A. Bojszko, et al. 2002. No association between asthma or allergy and the CCR5Delta 32 mutation. Arch Dis Child 86: 426.PubMedCrossRef Nagy, A., G.T. Kozma, A. Bojszko, et al. 2002. No association between asthma or allergy and the CCR5Delta 32 mutation. Arch Dis Child 86: 426.PubMedCrossRef
66.
Zurück zum Zitat McGinnis, R., F. Child, S. Clayton, et al. 2002. Further support for the association of CCR5 allelic variants with asthma susceptibility. Eur J Immunogenet 29: 525–528.PubMedCrossRef McGinnis, R., F. Child, S. Clayton, et al. 2002. Further support for the association of CCR5 allelic variants with asthma susceptibility. Eur J Immunogenet 29: 525–528.PubMedCrossRef
67.
Zurück zum Zitat Srivastava, P., P.J. Helms, D. Stewart, et al. 2003. Association of CCR5Delta32 with reduced risk of childhood but not adult asthma. Thorax 58: 222–226.PubMedCrossRef Srivastava, P., P.J. Helms, D. Stewart, et al. 2003. Association of CCR5Delta32 with reduced risk of childhood but not adult asthma. Thorax 58: 222–226.PubMedCrossRef
68.
Zurück zum Zitat Hall, I.P., A. Wheatley, G. Christie, et al. 1999. Association of CCR5 delta32 with reduced risk of asthma. Lancet 354: 1264–1265.PubMedCrossRef Hall, I.P., A. Wheatley, G. Christie, et al. 1999. Association of CCR5 delta32 with reduced risk of asthma. Lancet 354: 1264–1265.PubMedCrossRef
Metadaten
Titel
Is the CCR5 Δ 32 Mutation Associated with Immune System-Related Diseases?
verfasst von
Khodayar Ghorban
Maryam Dadmanesh
Gholamhossein Hassanshahi
Mohammad Momeni
Mohammad Zare-Bidaki
Mohammad Kazemi Arababadi
Derek Kennedy
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 3/2013
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9585-8

Weitere Artikel der Ausgabe 3/2013

Inflammation 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.